Novartis AG ADR (NVS)vsTravere Therapeutics Inc (TVTX)
NVS
Novartis AG ADR
$161.52
-1.40%
HEALTHCARE · Cap: $303.67B
TVTX
Travere Therapeutics Inc
$49.41
+0.30%
HEALTHCARE · Cap: $4.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9601% more annual revenue ($57.36B vs $591.33M). NVS leads profitability with a 17.5% profit margin vs -7.3%. NVS earns a higher WallStSmart Score of 48/100 (D+).
NVS
Hold48
out of 100
Grade: D+
TVTX
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.52
$65.96 premium
Margin of Safety
+19.5%
Fair Value
$62.60
Current Price
$49.41
$13.19 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Revenue surging 48.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
0.0% earnings growth
Operating margin of 2.3%
Trading at 190.0x book value
ROE of -69.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : TVTX
The strongest argument for TVTX centers on Revenue Growth. Revenue growth of 48.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : TVTX
The primary concerns for TVTX are EPS Growth, Operating Margin, Price/Book. Debt-to-equity of 25.16 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while TVTX is a hypergrowth play — different risk/reward profiles.
TVTX carries more volatility with a beta of 1.14 — expect wider price swings.
TVTX is growing revenue faster at 48.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 31/100), backed by strong 17.5% margins. TVTX offers better value entry with a 19.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Travere Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?